Developer docs
API playgroundTry for free, no card

Search company profiles

Xyall

Full company profile

uuid0003585

Namestring
Xyall
Legal namestring
Xyall B.V.
Websiteurl
xyall.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Xyall B.V. is a Dutch MedTech company headquartered in Eindhoven, Netherlands, founded in August 2018 by Guido du Pree and Hans van Wijngaarden—both former senior managers in Philips Healthcare's global digital pathology business. The company develops and commercializes the Tissector family of automated tissue dissection systems, which address the manual, error-prone tumor tissue dissection step in molecular pathology by integrating high-resolution slide imaging, image registration algorithms, precision robotics, and digital pathology workflow software. Its product portfolio comprises three integrated products: the Tissector High Throughput (1,800-slide capacity, >80 slides/hour, <0.1mm accuracy, 3 hours unattended) for large commercial molecular diagnostic labs; the Tissector Table Top (72-slide capacity, >30 slides/hour) for hospital-based labs; and the Tissector Annotation Suite, a remote pathologist workstation integrated with LIMS and IMS systems.

Xyall generates revenue primarily through direct enterprise sales of Tissector instruments (B2B IVD medical devices, quote-based, multi-year contracts) supplemented by recurring consumables (disposable scraping heads required per case) and software licensing through the Annotation Suite. Go-to-market combines direct field sales targeting high-volume commercial labs, academic medical centers, and hospital-based molecular pathology labs with channel partnerships—Motic for China and broader Asia, and Indica Labs for integrated HALO AP digital pathology workflow sales. The installed base includes 15+ US molecular pathology laboratories, with named reference customers including Labcorp, LUMC (Leiden University Medical Center), and InnoSIGN. The company holds ISO 13485:2016 certification (obtained April 2021, renewed January 2024) and has raised approximately €18.6 million across three funding rounds through February 2026.

Short descriptiontext

Xyall B.V. is a Dutch MedTech company that develops and sells automated tissue dissection systems (Tissector HT, Tissector Table Top, and Annotation Suite) for molecular pathology laboratories, serving commercial diagnostic labs, academic medical centers, and pharma research institutions globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEindhoven, Netherlands
HQ citystring
Eindhoven
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
automated tissue dissection, molecular pathology systems, digital pathology workstations, precision medical robotics, IVD medical devices
Industry3 codes
PRIMARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLAHAAAE
Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLACAMAJ
Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
NAICS code2 codes
  • Medical and Diagnostic Laboratories6215
  • Diagnostic Imaging Centers621512
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Surgical & Medical Instruments & Apparatus3841
Product category
Molecular Pathology Instrumentation
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Tissector Instrument Sales
TypeHardware Sales
Description

Sale of Tissector High Throughput and Tissector Table Top automated tissue dissection instruments to molecular pathology laboratories. The company manufactures and sells these IVD medical devices globally.

xyall.com
2Consumables (Scraping Heads)
TypeSubscription Recurring
Description

Recurring disposable consumables (scraping heads) required for each dissection case. Each case requires a new scraping head for cross-contamination prevention, creating recurring revenue from the installed base of instruments.

xyall.com
3Software Licenses (Annotation Suite)
TypeLicensing Royalties
Description

The Tissector Annotation Suite is bundled with instruments as workstation software for pathologists. Software may also be licensed separately or as part of integrated digital pathology workflows with partners such as Indica Labs HALO AP.

Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise medical device — no public pricing disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Tissector instruments are B2B medical devices sold via direct enterprise sales. Pricing is quote-based and not publicly disclosed.

xyall.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Tissector
Description

Automated tissue dissection system family including Tissector High Throughput for high-volume laboratories, Tissector Table Top for small to medium-sized labs, and Tissector Annotation Suite for remote pathologist annotation and workflow management.

Core offering1 text field

Xyall develops and manufactures the Tissector family of automated tissue dissection systems for molecular pathology laboratories. The Tissector High Throughput handles 1,800 slides and dissects over 80 slides per hour for high-volume commercial diagnostic labs, while the Tissector Table Top is a compact 72-slide system for small and medium hospital-based pathology labs. The Tissector Annotation Suite is a digital pathology workstation where pathologists remotely annotate regions of interest that are then automatically transferred to dissection slides via image registration for robotic scraping, replacing the manual tumor tissue macrodissection step used prior to DNA/RNA extraction and genomic profiling.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Superior to manual methods in scraping FFPE tissue within defined ROIs, minimizing excess paraffin, and delivering consistent tissue sections for downstream DNA/RNA extraction and comprehensive genomic and immune profiling (Labcorp study, SLAS2024)
+2 more records
Product overview1 text field

Xyall offers a family of automated tissue dissection solutions for molecular pathology laboratories. The product portfolio consists of the Tissector High Throughput system for large commercial molecular diagnostic laboratories, the Tissector Table Top system for small to medium sized hospital-based labs, and the Tissector Annotation Suite which serves as the pathologist workstation for all systems. All three products work together as an integrated solution, bridging the gap between histopathology and molecular pathology by automating the traditionally manual tissue dissection step in diagnostics. The Tissector solutions integrate high-resolution imaging, image registration, precision robotics, and workflow optimization.

Product and service3 records
1Tissector High Throughput
CategoryMolecular Pathology Instrumentation
Description

Industrial-scale automated tissue dissection system for high-volume molecular diagnostic laboratories. Holds up to 1,800 slides, dissects over 80 slides per hour with accuracy better than 0.1 mm, and runs up to 3 hours unattended. Fully integrated with LIMS/IMS and supports multiple sample tube formats.

2Tissector Table Top
CategoryMolecular Pathology Instrumentation
Description

Compact bench-top automated tissue dissection system for small to medium-sized molecular pathology laboratories. Holds 72 slides, dissects over 30 slides per hour with accuracy better than or equal to 0.1 mm, runs more than 2 hours uninterrupted, and supports batch operation with cases addable without interrupting operation.

3Tissector Annotation Suite
CategoryDigital Pathology Software
Description

Digital pathology workstation that lets pathologists remotely view and annotate cases, mark regions of interest at any magnification, and automatically transfer annotations to dissection slide images via image registration algorithms. Fully integrated with LIMS and IMS systems and supports any digital pathology file format.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-04-17
Description

Global strategic partnership bridging histology and molecular pathology. Combines Xyall's automated Tissector tissue dissection with Indica Labs' AI-powered HALO AP anatomic pathology image management and workflow software. HALO AP annotations are automatically simplified and transferred to Xyall's Tissector for tumor tissue dissection. Combined solution already in use in large commercial lab settings.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-04-17
Description

Academic collaboration with LUMC (with support of Indica Labs) on AI-enabled automated tissue macro-dissection in molecular pathology. Joint investigation presented at ECDP 2025 in Barcelona showed digital annotation and robotic dissection led to significant increases in tumor cellularity and VAF in NGS results.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-30
Description

Multi-year strategic partnership with world leader in microscopy and digital pathology systems. Motic provides digital pathology expertise, workflow integration, and scalable manufacturing capabilities. Joint product development for automated table-top tumor tissue dissection for hospital-based labs. Includes reseller and support agreement to accelerate delivery into Chinese and Asian markets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-13
Description

Strategic partner providing high-tech engineering expertise, including high-precision medical robotics and machine learning. First Xyall systems were manufactured at the Sioux Technologies facility in Eindhoven. Sioux has 750+ engineers providing software, mathware, mechatronics, and electronics expertise. Participated as investor in Series A, Series B, and 2026 funding rounds.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major pathology IVD and digital pathology player owned by Danaher, offering laser capture microdissection (LMD) systems, tissue processors, and staining instruments. Directly competes with Xyall in tissue dissection workflows and serves the same molecular pathology laboratory customers globally with substantially larger scale.

TypeDirect peer
Description

Specialized provider of laser capture microdissection (LCM) systems and cell manipulation tools for molecular pathology and biomedical research. Directly competes with Xyall's Tissector in the tissue dissection step, though MMI's technology is more research-focused versus Xyall's high-throughput diagnostic positioning.

TypeBroad incumbent
Description

Global leader in tissue diagnostics through its Ventana product line, offering staining systems, digital pathology scanners, and companion diagnostic assays. Competes with Xyall as the dominant incumbent in anatomic pathology IVD and has the resources to develop or acquire automated dissection technology.

TypeDirect peer
Description

Hungarian-based provider of digital pathology scanners, slide management systems, and tissue microarray instruments serving pathology laboratories. Comparable to Xyall as a European-headquartered digital pathology innovator serving molecular pathology workflows with mid-size scale.

TypeDirect peer
Description

Provider of HALO AP anatomic pathology image management and AI-powered annotation software, in a global strategic partnership with Xyall for integrated HALO AP + Tissector workflows. Comparable as a digital pathology platform serving the same molecular pathology customers, with overlapping product/market scope.

TypeBroad incumbent
Description

Manufacturer of NanoZoomer whole-slide imaging scanners and digital pathology solutions used by molecular pathology laboratories. Competes with Xyall's Tissector Annotation Suite in the digital pathology workflow space and serves the same enterprise laboratory customers.

TypeBroad incumbent
Description

Provider of spatial biology solutions including multiplexed tissue staining and imaging platforms (Opal/PhenoCycler) for molecular pathology. Comparable as a tissue-based molecular diagnostics company serving precision oncology applications, though focused on spatial analysis rather than bulk dissection.

TypeBroad incumbent
Description

Global digital pathology platform provider of IntelliSite scanners and pathology workflow software, and the former employer of Xyall's founders. Serves the same molecular pathology enterprise customers and competes in the digital annotation and workflow space integrated with the Tissector.

TypeDirect peer
Description

World leader in microscopy and digital pathology systems, in a multi-year strategic partnership with Xyall for joint product development and Asia/China distribution. Comparable as a pathology instrument and digital pathology provider with overlapping customer base in molecular pathology laboratories.

10Fluidigm (now Standard BioTools)
TypeEmerging player
Description

Provider of mass cytometry and molecular biology tools, including tissue imaging and molecular sample preparation technologies. Adjacent to Xyall in molecular pathology sample preparation, though focused on single-cell and proteomics applications rather than bulk tissue dissection.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Xyall

Molecular Pathology Instrumentationxyall.com

Xyall B.V. is a Dutch MedTech company that develops and sells automated tissue dissection systems (Tissector HT, Tissector Table Top, and Annotation Suite) for molecular pathology laboratories, serving commercial diagnostic labs, academic medical centers, and pharma research institutions globally.

What Xyall does

Xyall B.V. is a Dutch MedTech company headquartered in Eindhoven, Netherlands, founded in August 2018 by Guido du Pree and Hans van Wijngaarden—both former senior managers in Philips Healthcare's global digital pathology business. The company develops and commercializes the Tissector family of automated tissue dissection systems, which address the manual, error-prone tumor tissue dissection step in molecular pathology by integrating high-resolution slide imaging, image registration algorithms, precision robotics, and digital pathology workflow software. Its product portfolio comprises three integrated products: the Tissector High Throughput (1,800-slide capacity, >80 slides/hour, <0.1mm accuracy, 3 hours unattended) for large commercial molecular diagnostic labs; the Tissector Table Top (72-slide capacity, >30 slides/hour) for hospital-based labs; and the Tissector Annotation Suite, a remote pathologist workstation integrated with LIMS and IMS systems.

Xyall generates revenue primarily through direct enterprise sales of Tissector instruments (B2B IVD medical devices, quote-based, multi-year contracts) supplemented by recurring consumables (disposable scraping heads required per case) and software licensing through the Annotation Suite. Go-to-market combines direct field sales targeting high-volume commercial labs, academic medical centers, and hospital-based molecular pathology labs with channel partnerships—Motic for China and broader Asia, and Indica Labs for integrated HALO AP digital pathology workflow sales. The installed base includes 15+ US molecular pathology laboratories, with named reference customers including Labcorp, LUMC (Leiden University Medical Center), and InnoSIGN. The company holds ISO 13485:2016 certification (obtained April 2021, renewed January 2024) and has raised approximately €18.6 million across three funding rounds through February 2026.

Xyall firmographics

Firmographics
Name
Xyall
Legal name
Xyall B.V.
Website
https://xyall.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Xyall B.V. is a Dutch MedTech company that develops and sells automated tissue dissection systems (Tissector HT, Tissector Table Top, and Annotation Suite) for molecular pathology laboratories, serving commercial diagnostic labs, academic medical centers, and pharma research institutions globally.
Ownership category
akta.pro rank

Xyall industry classification

Industry
Product category
Molecular Pathology Instrumentation
NAICS
Medical and Diagnostic Laboratories (6215), Diagnostic Imaging Centers (621512)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLAHAAAE
Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLACAMAJ
Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics

Keywords

  • Automated tissue dissection
  • Molecular pathology systems
  • Digital pathology workstations
  • Precision medical robotics
  • IVD medical devices

Where Xyall is headquartered

Location

Headquarters

HQ city
Eindhoven
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

Xyall business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Tissector Instrument Sales: Sale of Tissector High Throughput and Tissector Table Top automated tissue dissection instruments to molecular pathology laboratories. The company manufactures and sells these IVD medical devices globally.
  2. Consumables (Scraping Heads): Recurring disposable consumables (scraping heads) required for each dissection case. Each case requires a new scraping head for cross-contamination prevention, creating recurring revenue from the installed base of instruments.
  3. Software Licenses (Annotation Suite): The Tissector Annotation Suite is bundled with instruments as workstation software for pathologists. Software may also be licensed separately or as part of integrated digital pathology workflows with partners such as Indica Labs HALO AP.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise medical device — no public pricing disclosed

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Xyall product offering

Product offering

Core offering

Xyall develops and manufactures the Tissector family of automated tissue dissection systems for molecular pathology laboratories. The Tissector High Throughput handles 1,800 slides and dissects over 80 slides per hour for high-volume commercial diagnostic labs, while the Tissector Table Top is a compact 72-slide system for small and medium hospital-based pathology labs. The Tissector Annotation Suite is a digital pathology workstation where pathologists remotely annotate regions of interest that are then automatically transferred to dissection slides via image registration for robotic scraping, replacing the manual tumor tissue macrodissection step used prior to DNA/RNA extraction and genomic profiling.

Product overview

Xyall offers a family of automated tissue dissection solutions for molecular pathology laboratories. The product portfolio consists of the Tissector High Throughput system for large commercial molecular diagnostic laboratories, the Tissector Table Top system for small to medium sized hospital-based labs, and the Tissector Annotation Suite which serves as the pathologist workstation for all systems. All three products work together as an integrated solution, bridging the gap between histopathology and molecular pathology by automating the traditionally manual tissue dissection step in diagnostics. The Tissector solutions integrate high-resolution imaging, image registration, precision robotics, and workflow optimization.

Differentiator

Problem solved

Functional benefit

Brands

  • Tissector: Automated tissue dissection system family including Tissector High Throughput for high-volume laboratories, Tissector Table Top for small to medium-sized labs, and Tissector Annotation Suite for remote pathologist annotation and workflow management.

Products and services

  • Tissector High Throughput Industrial-scale automated tissue dissection system for high-volume molecular diagnostic laboratories. Holds up to 1,800 slides, dissects over 80 slides per hour with accuracy better than 0.1 mm, and runs up to 3 hours unattended. Fully integrated with LIMS/IMS and supports multiple sample tube formats.
  • Tissector Table Top Compact bench-top automated tissue dissection system for small to medium-sized molecular pathology laboratories. Holds 72 slides, dissects over 30 slides per hour with accuracy better than or equal to 0.1 mm, runs more than 2 hours uninterrupted, and supports batch operation with cases addable without interrupting operation.
  • Tissector Annotation Suite Digital pathology workstation that lets pathologists remotely view and annotate cases, mark regions of interest at any magnification, and automatically transfer annotations to dissection slide images via image registration algorithms. Fully integrated with LIMS and IMS systems and supports any digital pathology file format.

Quantifiable outcome

  • Superior to manual methods in scraping FFPE tissue within defined ROIs, minimizing excess paraffin, and delivering consistent tissue sections for downstream DNA/RNA extraction and comprehensive genomic and immune profiling (Labcorp study, SLAS2024)
  • +2 more outcomes

Companies that use Xyall

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Xyall technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature6 records

Xyall partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Indica LabscoreTechnology or Integration · 17 April 2023Global strategic partnership bridging histology and molecular pathology. Combines Xyall's automated Tissector tissue dissection with Indica Labs' AI-powered HALO AP anatomic pathology image management and workflow software. HALO AP annotations are automatically simplified and transferred to Xyall's Tissector for tumor tissue dissection. Combined solution already in use in large commercial lab settings.
  • LUMC (Leiden University Medical Center)minorStrategic or Co-development Partner · 17 April 2023Academic collaboration with LUMC (with support of Indica Labs) on AI-enabled automated tissue macro-dissection in molecular pathology. Joint investigation presented at ECDP 2025 in Barcelona showed digital annotation and robotic dissection led to significant increases in tumor cellularity and VAF in NGS results.
  • MoticcoreStrategic or Co-development Partner · 30 September 2020Multi-year strategic partnership with world leader in microscopy and digital pathology systems. Motic provides digital pathology expertise, workflow integration, and scalable manufacturing capabilities. Joint product development for automated table-top tumor tissue dissection for hospital-based labs. Includes reseller and support agreement to accelerate delivery into Chinese and Asian markets.
  • Sioux TechnologiescoreStrategic or Co-development Partner · 13 January 2020Strategic partner providing high-tech engineering expertise, including high-precision medical robotics and machine learning. First Xyall systems were manufactured at the Sioux Technologies facility in Eindhoven. Sioux has 750+ engineers providing software, mathware, mechatronics, and electronics expertise. Participated as investor in Series A, Series B, and 2026 funding rounds.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Xyall competitors and assessment

Company assessment

Broad incumbents

  • Leica Biosystems (Danaher): Major pathology IVD and digital pathology player owned by Danaher, offering laser capture microdissection (LMD) systems, tissue processors, and staining instruments. Directly competes with Xyall in tissue dissection workflows and serves the same molecular pathology laboratory customers globally with substantially larger scale.
  • Roche Diagnostics (Ventana): Global leader in tissue diagnostics through its Ventana product line, offering staining systems, digital pathology scanners, and companion diagnostic assays. Competes with Xyall as the dominant incumbent in anatomic pathology IVD and has the resources to develop or acquire automated dissection technology.
  • Hamamatsu Photonics: Manufacturer of NanoZoomer whole-slide imaging scanners and digital pathology solutions used by molecular pathology laboratories. Competes with Xyall's Tissector Annotation Suite in the digital pathology workflow space and serves the same enterprise laboratory customers.
  • Akoya Biosciences: Provider of spatial biology solutions including multiplexed tissue staining and imaging platforms (Opal/PhenoCycler) for molecular pathology. Comparable as a tissue-based molecular diagnostics company serving precision oncology applications, though focused on spatial analysis rather than bulk dissection.
  • Philips Digital Pathology: Global digital pathology platform provider of IntelliSite scanners and pathology workflow software, and the former employer of Xyall's founders. Serves the same molecular pathology enterprise customers and competes in the digital annotation and workflow space integrated with the Tissector.

Direct peers

  • Molecular Machines & Industries (MMI): Specialized provider of laser capture microdissection (LCM) systems and cell manipulation tools for molecular pathology and biomedical research. Directly competes with Xyall's Tissector in the tissue dissection step, though MMI's technology is more research-focused versus Xyall's high-throughput diagnostic positioning.
  • 3DHISTECH: Hungarian-based provider of digital pathology scanners, slide management systems, and tissue microarray instruments serving pathology laboratories. Comparable to Xyall as a European-headquartered digital pathology innovator serving molecular pathology workflows with mid-size scale.
  • Indica Labs: Provider of HALO AP anatomic pathology image management and AI-powered annotation software, in a global strategic partnership with Xyall for integrated HALO AP + Tissector workflows. Comparable as a digital pathology platform serving the same molecular pathology customers, with overlapping product/market scope.
  • Motic: World leader in microscopy and digital pathology systems, in a multi-year strategic partnership with Xyall for joint product development and Asia/China distribution. Comparable as a pathology instrument and digital pathology provider with overlapping customer base in molecular pathology laboratories.

Emerging players

  • Fluidigm (now Standard BioTools): Provider of mass cytometry and molecular biology tools, including tissue imaging and molecular sample preparation technologies. Adjacent to Xyall in molecular pathology sample preparation, though focused on single-cell and proteomics applications rather than bulk tissue dissection.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Xyall social profiles

Digital presence

Xyall compliance and trust

Trust signal

Compliance1 record

Xyall financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Xyall leadership team

Management profile

Number of profiles

Profiles9 records

Xyall funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Xyall M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xyall

What does Xyall do?

Xyall develops and manufactures the Tissector family of automated tissue dissection systems for molecular pathology laboratories. The Tissector High Throughput handles 1,800 slides and dissects over 80 slides per hour for high-volume commercial diagnostic labs, while the Tissector Table Top is a compact 72-slide system for small and medium hospital-based pathology labs. The Tissector Annotation Suite is a digital pathology workstation where pathologists remotely annotate regions of interest that are then automatically transferred to dissection slides via image registration for robotic scraping, replacing the manual tumor tissue macrodissection step used prior to DNA/RNA extraction and genomic profiling.

Is Xyall a public or private company?

Xyall is a private company. It is classified as venture growth investor backed and is currently operating.

When was Xyall founded?

Xyall was founded in 2018. It employs 11 to 50 people.

Where is Xyall based?

Xyall is headquartered in Eindhoven, Netherlands, in the Europe region.

How does Xyall make money?

Three revenue lines are on record. Tissector Instrument Sales are the primary driver. The others are consumables (Scraping Heads) and software Licenses (Annotation Suite).

Who are Xyall's main competitors?

Broad incumbents on record are Leica Biosystems (Danaher), Roche Diagnostics (Ventana), Hamamatsu Photonics, Akoya Biosciences and Philips Digital Pathology. Direct peers are Molecular Machines & Industries (MMI), 3DHISTECH, Indica Labs and Motic. Fluidigm (now Standard BioTools) is listed as an emerging player.

Does Xyall have an API?

No public API is recorded for Xyall.

What industry is Xyall in?

Xyall's product category is Molecular Pathology Instrumentation. Its primary akta.pro industry code is HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow, with a secondary code of HLAHAAAE, Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics). Its NAICS code is 6215 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Xyall: €7.6 Million Raised To Accelerate Global Rollout Of Tissue Dissection SystemXyall BV, a Dutch molecular pathology innovator, has raised €7.6 million in a funding round led by Capricorn Partners through its Capricorn Healthtech Fund II, with participation from Sioux Technologies, Brabant Development Agency (BOM), Health Investment Partners, and private investors. The proceeds will accelerate global rollout of the Tissector TableTop, an automated tissue dissection system currently deployed in over 15 Tier 1 commercial, academic, pharmaceutical, and research laboratories in the United States. The platform addresses a largely manual and labor-intensive process in molecular pathology labs, which face mounting pressure to deliver faster, more precise diagnostic results amid a global shortage of specialized staff.EU-StartupsEindhoven’s MedTech startup Xyall secures €7.6 million for global rollout of its automated tissue dissection systemEindhoven-based MedTech startup Xyall has secured €7.6 million in investment from a consortium led by Capricorn Partners, along with existing investors Sioux Technologies, Brabant Development Agency, and Health Investment Partners, to support the global rollout of its automated Tissector Table Top tissue dissection system. Founded in 2018, Xyall's solution automates the traditionally manual and error-prone tissue dissection workflow for molecular pathology laboratories, addressing issues of subjectivity, cross-contamination, and labour shortages. The Tissector Table Top, which can dissect over 30 slides per hour with sub-millimetre accuracy, is already deployed in more than 15 molecular pathology laboratories across the United States.DistilinfoXyall Secures €7.6M for Pathology AutomationXyall, an Eindhoven-based MedTech startup, has raised €7.6 million in strategic investment led by Capricorn Partners through its Healthtech Fund II, with participation from existing investors Sioux Technologies, Brabant Development Agency, Health Investment Partners, and private investors. The funding will accelerate global deployment of the company's Tissector Table Top automated tissue dissection system, which already serves more than 15 molecular pathology laboratories across the United States. Founded in 2018 by Guido du Pree and Hans van Wijngaarden, Xyall's technology addresses the manual workflow bottleneck in tissue sample preparation for molecular diagnostics.FoundersTodayXyall raises €7.6M to scale automated Tissue Dissection WorldwideEindhoven-based MedTech startup Xyall has secured €7.6 million in funding, led by Capricorn Partners through its Capricorn Healthtech Fund II, to expand its automated tissue dissection technology for molecular pathology laboratories globally. The company's Tissector Table Top system, already deployed in over 15 US molecular pathology labs, automates the traditionally manual tissue dissection step in diagnostics by integrating high-resolution imaging, image registration, and precision robotics. CEO Guido du Pree noted that the technology addresses the growing gap between advanced molecular testing capabilities and the still-manual process of tumour tissue selection.BebeezEindhoven’s MedTech startup Xyall secures €7.6 million for global rollout of its automated tissue dissection system – BeBeez InternationalXyall, a MedTech startup based in Eindhoven, secured €7.6 million in funding to expand the use of its automated tissue dissection system globally. The funding aims to support the rollout of its solutions for molecular pathology laboratories, addressing inefficiencies and shortages in lab technicians.XyallXyall and Indica Labs forge global collaboration MedtechXyall BV, a Dutch molecular pathology company, has raised €7.6 million in a funding round led by Capricorn Partners through its Capricorn Healthtech Fund II, with participation from existing investors Sioux Technologies, Brabant Development Agency (BOM), Health Investment Partners, and private investors. The investment will accelerate the global rollout of Xyall's Tissector TableTop automated tissue dissection system, which is already deployed at more than 15 molecular pathology laboratories in the United States across commercial, academic, pharmaceutical, and research institutions. The company says its technology addresses the growing pressure on pathology labs to deliver faster, more accurate results amid a global shortage of specialized laboratory technicians.Clinical Lab ProductsXyall, Indica Labs Partner to Improve Precision Oncology WorkflowsXyall and Indica Labs announced a global strategic partnership to automate tumor tissue dissection for molecular diagnostics. The collaboration combines Xyall's Tissector systems with Indica Labs' HALO AP software, aiming to increase throughput and accuracy while reducing costs. Future deployments will include AI-based tumor detection and cell quantification.PR NewswireMolecular and digital pathology innovators Xyall and Indica Labs forge global collaboration to transform precision oncology workflowsXyall and Indica Labs announced a global strategic partnership to combine Xyall's automated tissue dissection systems with Indica Labs' HALO AP digital pathology platform. The collaboration aims to automate tumor tissue dissection for molecular diagnostics, improving throughput and accuracy while reducing costs. Future deployments will include AI-based tumor detection and cell quantification.Silicon CanalsDutch-based Xyall secures €6M to help pathologists obtain more reliable molecular diagnostic test resultsEindhoven-based Xyall BV has secured €6 million in Series B funding to accelerate the commercialization of its automated tissue dissection systems, the Tissector High Throughput and Tissector Table Top. The investment, led by Health Investment Partners with participation from existing backers like Sioux Technologies, aims to address manual inefficiencies and contamination risks in molecular pathology workflows. Xyall plans to launch its compact Table Top system later this year at the Annual Molecular Pathology meeting in the US.XyallMedtech innovator Xyall secures €6M Series B financingXyall BV, a global innovator in molecular pathology, has secured €6 million in Series B financing to advance the commercialization of its automated tissue dissection systems. The investment was led by Health Investment Partners (HIP) and includes participation from Sioux Technologies, the Brabant Development Agency, and private investors. Xyall aims to improve the efficiency and accuracy of molecular diagnostic workflows in laboratories dealing with cancer treatments.